Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-15
DOI
10.1038/s41598-017-04301-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab
- (2016) Elham Abu Sharieh et al. GENE
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
- (2015) Sharon T. Wilks BREAST
- In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib
- (2015) Ashok K. Chakraborty et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
- (2015) Nadeera De Silva et al. BRITISH JOURNAL OF CANCER
- Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment
- (2015) Sarah L. Larsen et al. PLoS One
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
- (2014) G Peiró et al. BRITISH JOURNAL OF CANCER
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
- (2014) Z. Zhang et al. CLINICAL CANCER RESEARCH
- Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
- (2014) Gillian M. Keating DRUGS
- Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
- (2014) Jayakumar S. Poovassery et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
- (2014) Simonetta M. Leto et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
- (2014) Helmout Modjtahedi et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
- (2013) Nikolaos Ioannou et al. BMC CANCER
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy
- (2013) Abhilasha Sinha et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Targeted therapy for HER2 positive breast cancer
- (2013) Jason A Incorvati et al. Journal of Hematology & Oncology
- A gene expression profile indicative of early stage HER2 targeted therapy response
- (2013) Fiona O’Neill et al. Molecular Cancer
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
- (2013) D Wetterskog et al. ONCOGENE
- Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
- (2012) Caterina Carmi et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
- (2012) G Minuti et al. BRITISH JOURNAL OF CANCER
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
- (2011) N Ioannou et al. BRITISH JOURNAL OF CANCER
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- (2011) Joan T. Garrett et al. CANCER BIOLOGY & THERAPY
- Truncated HER2: implications for HER2-targeted therapeutics
- (2011) Radoslaw Zagozdzon et al. DRUG DISCOVERY TODAY
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- The HER2 testing conundrum
- (2010) Malorye Allison NATURE BIOTECHNOLOGY
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions
- (2009) Alberto Ocaña et al. CANCER TREATMENT REVIEWS
- Targeting Src in breast cancer
- (2008) R. S. Finn ANNALS OF ONCOLOGY
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started